Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset Diabetes
The University of Texas Health Science Center at San Antonio
256 participants
Nov 7, 2024
INTERVENTIONAL
Conditions
Summary
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.
Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.
Sitagliptin: will be administered as a 100mg dose once daily.
Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06246799